EP2266542A3 - Libération regulée de compositions nanoparticulaires - Google Patents

Libération regulée de compositions nanoparticulaires Download PDF

Info

Publication number
EP2266542A3
EP2266542A3 EP10179341.2A EP10179341A EP2266542A3 EP 2266542 A3 EP2266542 A3 EP 2266542A3 EP 10179341 A EP10179341 A EP 10179341A EP 2266542 A3 EP2266542 A3 EP 2266542A3
Authority
EP
European Patent Office
Prior art keywords
controlled release
nanoparticulate compositions
release nanoparticulate
release
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10179341.2A
Other languages
German (de)
English (en)
Other versions
EP2266542A2 (fr
Inventor
Jon Swanson
Rajeev A Jain
Robert Hontz
John G. Devane
Kenneth Iain Cumming
Maurice Joseph Anthony Clancy
Janet Elizabeth Codd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Pharma International DAC
Original Assignee
Elan Pharma International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/337,675 external-priority patent/US8293277B2/en
Application filed by Elan Pharma International Ltd filed Critical Elan Pharma International Ltd
Publication of EP2266542A2 publication Critical patent/EP2266542A2/fr
Publication of EP2266542A3 publication Critical patent/EP2266542A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP10179341.2A 1998-10-01 1999-10-01 Libération regulée de compositions nanoparticulaires Withdrawn EP2266542A3 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16435198A 1998-10-01 1998-10-01
US09/337,675 US8293277B2 (en) 1998-10-01 1999-06-22 Controlled-release nanoparticulate compositions
EP99950105A EP1117384A1 (fr) 1998-10-01 1999-10-01 Liberation regulee de compositions nanoparticulaires

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP99950105.9 Division 1999-10-01

Publications (2)

Publication Number Publication Date
EP2266542A2 EP2266542A2 (fr) 2010-12-29
EP2266542A3 true EP2266542A3 (fr) 2013-07-31

Family

ID=26860472

Family Applications (2)

Application Number Title Priority Date Filing Date
EP10179341.2A Withdrawn EP2266542A3 (fr) 1998-10-01 1999-10-01 Libération regulée de compositions nanoparticulaires
EP99950105A Ceased EP1117384A1 (fr) 1998-10-01 1999-10-01 Liberation regulee de compositions nanoparticulaires

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP99950105A Ceased EP1117384A1 (fr) 1998-10-01 1999-10-01 Liberation regulee de compositions nanoparticulaires

Country Status (6)

Country Link
US (5) US20070048378A1 (fr)
EP (2) EP2266542A3 (fr)
JP (4) JP2002525311A (fr)
AU (1) AU6283299A (fr)
CA (1) CA2346001C (fr)
WO (1) WO2000018374A1 (fr)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
CA2348452A1 (fr) * 1998-10-27 2000-05-04 Biovail Technologies Ltd. Microparticules contenant du peg et/ou des esters glyceriliques de peg
US7815937B2 (en) * 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6969529B2 (en) 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
ATE404172T1 (de) 1998-12-30 2008-08-15 Dexcel Ltd Dispergierbares konzentrat zur verabreichung von cyclosporin
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
KR100793668B1 (ko) 1999-12-08 2008-01-10 파마시아 코포레이션 강화된 생체이용률을 지닌 고체상 형태의 셀레콕시브
CN1402629A (zh) 1999-12-23 2003-03-12 辉瑞产品公司 提供提高的药物浓度的药物组合物
MY120279A (en) 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7998507B2 (en) 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
AU2001297844A1 (en) * 2000-11-20 2002-12-03 Elan Pharma International Ltd. Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
BR0210520A (pt) 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de dispersões de fármacos amorfos misturados com polìmeros
AUPR602401A0 (en) 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release delivery system
AUPR602501A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release pharmaceutical composition
US7105178B2 (en) 2001-07-17 2006-09-12 Sun Pharmaceutical Industries Limited Cardiotonic composition
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
BR0212833A (pt) 2001-09-26 2004-10-13 Baxter Int Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
ES2292848T3 (es) 2001-10-12 2008-03-16 Elan Pharma International Limited Composiciones que tienen una combinacion de caracteristicas de liberacion inmediata y liberacion controlada.
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
GB0127805D0 (en) 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
EP1458365A1 (fr) * 2001-12-21 2004-09-22 Celator Technologies Inc. Vecteur ameliore a base de polymere et de lipide
EP1471887B1 (fr) 2002-02-04 2010-04-21 Elan Pharma International Ltd. Compositions nanoparticulaires a stabilisateur superficiel de lysozyme
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
EP1478349A1 (fr) * 2002-02-21 2004-11-24 Amarin Development AB Methode d'administration de particules a dimensions nanometriques provenant d'une substance active contenue dans une composition pharmaceutique a diffusion regulee et a usage par voie orale
EP1490025B1 (fr) * 2002-03-20 2008-02-13 Elan Pharma International Limited Compositions nanoparticulaires d'inhibiteurs de la proteine kinase activee par des mitogenes (map)
WO2003080027A1 (fr) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Compositions nanoparticulaires d'inhibiteurs d'angiogenese
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
EP2283864A1 (fr) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Composition liquide contenant des nanoparticules stabilisées d'une substance active
FR2842736B1 (fr) 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
ATE487470T1 (de) * 2002-09-11 2010-11-15 Elan Pharma Int Ltd Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse
CA2504610C (fr) * 2002-11-12 2012-02-21 Elan Pharma International Ltd. Formes posologiques solides a desintegration rapide non friables et comprenant du pullulane
EP1589951B1 (fr) * 2003-01-03 2017-08-09 Supernus Pharmaceuticals, Inc. Utilisation d'un melange de deux ou de plusieurs materiaux enteriques afin de reguler la liberation de medicaments via une membrane ou une matrice dans des therapies systemiques
SE526027C2 (sv) 2003-05-23 2005-06-14 Gambro Lundia Ab Biokompatibel polymerkomposition, förfarande för beredning av en biokompatibel sampolymerkomposition, artikel med en film av en polymerkomposition och användning av en biokompatibel polymerkomposition för en medicinsk anordning
CA2524118C (fr) * 2003-05-23 2012-04-24 Gambro Lundia Ab Composition de polymere biocompatible contenant un complexe du bismuth
NZ527142A (en) 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
CA2631757A1 (fr) * 2005-12-02 2007-06-07 Elan Pharma International Limited Nouvelles compositions de mometasone et procedes de fabrication et utilisation de celles-ci
ES2593047T3 (es) 2006-02-03 2016-12-05 Opko Renal, Llc Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
SG170047A1 (en) * 2006-05-30 2011-04-29 Elan Pharma Int Ltd Nanoparticulate posaconazole formulations
ES2670029T3 (es) 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
AU2007264418B2 (en) * 2006-06-30 2012-05-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
JP2009543797A (ja) * 2006-07-10 2009-12-10 エラン ファーマ インターナショナル，リミティド ナノ粒子ソラフェニブ製剤
HUE046441T2 (hu) * 2006-09-26 2020-02-28 Novartis Ag S1P modulátort tartalmazó gyógyászati készítmények
US11752158B2 (en) 2007-04-25 2023-09-12 Eirgen Pharma Ltd. Method of treating vitamin D insufficiency and deficiency
KR20190028822A (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
HUE073014T2 (hu) 2007-04-25 2025-12-28 Opko Renal Llc Eljárás a másodlagos hyperparathyreoidismus biztonságos és hatékony kezelésére és megelõzésére krónikus vesebetegség esetén
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
EP2152274A4 (fr) * 2007-05-07 2010-07-21 Questor Pharmaceuticals Inc Administration par voie nasale de benzodiazépines
US20100172982A1 (en) * 2007-05-23 2010-07-08 Sun Pharmaceutical Industries Limited Sustained release formulations of divalproex sodium
WO2008155620A1 (fr) * 2007-06-20 2008-12-24 Develco Pharma Schweiz Ag Forme posologique contenant une matrice dispersible de granulés à libération entretenue
IS8660A (is) * 2007-07-02 2009-01-03 Actavis Group Ptc Ehf. Gliklasíð lyfjasamsetning
TWI441658B (zh) 2008-03-11 2014-06-21 Takeda Pharmaceutical 口腔崩解固體製劑
US20090258865A1 (en) 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
EP2281058B1 (fr) 2008-04-02 2016-06-29 Opko Ireland Global Holdings, Ltd. Procédés, compositions, utilisations, et kits utiles pour la carence en vitamine d et des troubles associés
US7828996B1 (en) 2009-03-27 2010-11-09 Abbott Cardiovascular Systems Inc. Method for the manufacture of stable, nano-sized particles
CA2757979A1 (fr) * 2009-04-09 2010-10-14 Alkermes Pharma Ireland Limited Compositions de clozapine a liberation controlee
EP3167875A1 (fr) 2009-05-27 2017-05-17 Alkermes Pharma Ireland Limited Réduction d'agrégation de type paillettes dans des compositions de meloxicam nanoparticulaire
IT1397000B1 (it) * 2009-11-12 2012-12-20 Antropoli Uso di un preparato basato sulla nifedipina per il trattamento del vaginismo
WO2011086047A1 (fr) 2010-01-13 2011-07-21 Azur Pharma Limited Méthode de titration de la clozapine
US8828445B2 (en) 2010-03-22 2014-09-09 Bio-Synectics Inc. Method for preparing nano-particles utilizing a saccharide anti-coagulant
JP2011207988A (ja) * 2010-03-29 2011-10-20 Sumitomo Chemical Co Ltd 樹脂用の加工安定化剤、該加工安定化剤を含む樹脂組成物、および樹脂の加工安定性を向上させる方法
WO2011123476A1 (fr) 2010-03-29 2011-10-06 Cytochroma Inc. Procédés et compositions pour réduction de taux d'hormone parathyroïde
EP3335711A1 (fr) * 2010-03-31 2018-06-20 Supernus Pharmaceuticals, Inc. Formulations de mazindol
WO2011146583A2 (fr) 2010-05-19 2011-11-24 Elan Pharma International Limited Formulations de cinacalcet nanoparticulaire
US8916588B2 (en) * 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) * 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) * 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9498447B2 (en) * 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8927010B2 (en) * 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
AU2012230733B2 (en) * 2011-03-23 2016-10-20 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
CA2835293C (fr) * 2011-06-08 2020-08-18 Sti Pharma, Llc Preparation organique pharmaceutique hydrosoluble a absorption controlee administree une fois par jour
ES2683902T3 (es) 2011-06-14 2018-09-28 Hale Biopharma Ventures, Llc Administración de benzodiacepina
FR2987268B1 (fr) 2012-02-28 2014-07-11 Ammtek Formulations liquides de sulfamides hypoglycemiants
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
PT107846B (pt) * 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US20180371158A1 (en) * 2015-12-18 2018-12-27 Abraham Joy Peptidomimetic polymers as controlled release matrices for small molecules, biologicals, synthetic or semi-synthetic macromolecules
JP7032322B2 (ja) 2016-03-28 2022-03-08 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ治療法
MX395554B (es) 2016-09-17 2025-03-25 Intas Pharmaceuticals Ltd Composición farmacéutica de clozapina de liberación prolongada.
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
SG11201903829PA (en) * 2016-10-31 2019-05-30 Neurim Pharma 1991 Melatonin mini-tablets and method of manufacturing the same
IL270654B2 (en) * 2017-05-17 2024-07-01 Confluence Pharmaceuticals Llc Formulations of homotaurines and salts thereof
JP2024521399A (ja) 2021-06-10 2024-05-31 ニューレリス、インク． 小児患者における発作性障害を治療するための組成物および方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010760A1 (fr) * 1991-12-05 1993-06-10 Alfatec-Pharma Gmbh Medicament a effet retard contenant de l'ibuprofene et son utilisation
WO1993010767A1 (fr) * 1991-12-05 1993-06-10 Alfatec-Pharma Gmbh Forme d'administration perorale de medicaments peptidiques, notamment l'insuline
WO1998035666A1 (fr) * 1997-02-13 1998-08-20 Nanosystems Llc Preparation de pastilles de naproxene nanoparticulaire

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US48378A (en) * 1865-06-27 Improvement
JPS4843848B1 (fr) * 1970-11-05 1973-12-21
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4389397A (en) * 1980-08-04 1983-06-21 Merck & Co., Inc. Solubilization of ivermectin in water
ZA822995B (en) * 1981-05-21 1983-12-28 Wyeth John & Brother Ltd Slow release pharmaceutical composition
JPS5846019A (ja) * 1981-09-14 1983-03-17 Kanebo Ltd 持続性ニフエジピン製剤
JPS59101423A (ja) * 1982-12-02 1984-06-12 Takada Seiyaku Kk 新規なニフエジピン固形製剤
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung
AU570998B2 (en) * 1983-09-07 1988-03-31 Takeda Chemical Industries Ltd. Topical steroid compositions for acne
US4917816A (en) * 1984-01-03 1990-04-17 Abco Industries, Inc. Stabilized peroxide compositions and process for producing same
JPH0621066B2 (ja) * 1984-03-14 1994-03-23 杏林製薬株式会社 ３―イソブチリル―２―イソプロピルピラゾロ〔１，５―ａ〕ピリジンの徐放性医薬品組成物
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
DE3421468A1 (de) * 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4757059A (en) * 1984-08-14 1988-07-12 International Copper Research Association Method for treating convulsions and epilepsy with organic copper compounds
CA1264566A (fr) * 1984-09-05 1990-01-23 Tetsuji Iwasaki Poudre fine biocide, sa fabrication et suspension pour usage agricole renfermant ladite poudre
US4783484A (en) * 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
US4727077A (en) * 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
JPS61218516A (ja) * 1985-03-25 1986-09-29 Ichimaru Fuarukosu Kk 徐放性マイクロカプセルの製造法
US4657902A (en) * 1985-03-25 1987-04-14 The Rockefeller University Therapeutic use of tin mesoporphyrin
SE455836B (sv) * 1985-10-11 1988-08-15 Haessle Ab Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
JPH0684299B2 (ja) * 1985-11-26 1994-10-26 鐘紡株式会社 硝酸イソソルビド徐放性製剤の製造法
JPS62185013A (ja) * 1986-02-08 1987-08-13 Green Cross Corp:The 易吸収性医薬組成物
DE3610037A1 (de) * 1986-03-21 1987-09-24 Schering Ag Nifedipinkombinationspraeparat
MX9203130A (es) * 1986-05-06 1992-07-01 Genetics Inst Produccion de m-csf
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
DE3620685A1 (de) * 1986-06-20 1987-12-23 Henkel Kgaa Neue mittel zur abdeckung unverletzter und/oder verletzter bereiche menschlicher oder tierischer haut
EP0262560A3 (fr) * 1986-09-29 1989-07-05 Ishihara Sangyo Kaisha, Ltd. Composés benzoyl urées
US4983605A (en) * 1986-10-23 1991-01-08 Ishihara Sangyo Kaisha Ltd. Pharmaceutical composition
FR2608942B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules
FR2608988B1 (fr) 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
JP2661709B2 (ja) * 1988-07-08 1997-10-08 ダウ・ケミカル日本株式会社 高活性な農薬水和剤の製法
FR2634376B1 (fr) * 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
ES2052016T3 (es) * 1988-09-29 1994-07-01 Shiseido Co Ltd Composicion emulsionada.
JPH02196719A (ja) * 1989-01-24 1990-08-03 Green Cross Corp:The 粉末状医薬組成物
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5156767A (en) * 1990-01-16 1992-10-20 Conoco Inc. Emulsion breaking using alkylphenol-polyethylene oxide-acrylate polymer coated coalescer material
GB9005498D0 (en) 1990-03-12 1990-05-09 Beecham Group Plc Composition
US5110605A (en) 1990-08-21 1992-05-05 Oramed, Inc. Calcium polycarbophil-alginate controlled release composition and method
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
CA2112905A1 (fr) * 1991-07-05 1993-01-21 Michael R. Violante Particules poreuses ultra petites, non solidarisees, a bulles de gaz piegees
US5776563A (en) * 1991-08-19 1998-07-07 Abaxis, Inc. Dried chemical compositions
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5188755A (en) * 1991-10-10 1993-02-23 Block Drug Company Surface erodible controlled releasing, free standing cleansing block and cleaning method for the domestic water closet
US5610294A (en) 1991-10-11 1997-03-11 The Du Pont Merck Pharmaceutical Company Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
US5300739A (en) * 1992-05-26 1994-04-05 Otis Elevator Company Cyclically varying an elevator car's assigned group in a system where each group has a separate lobby corridor
DE69309056T2 (de) * 1992-06-10 1997-09-18 Nanosystems L.L.C., Collegeville, Pa. Oberflaechenmodifizierte nsaid nanopartikeln
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
JPH06186817A (ja) * 1992-09-21 1994-07-08 Toshiba Corp 画像形成装置
DE69327542T2 (de) * 1992-11-17 2000-07-06 Yoshitomi Pharmaceutical Industries, Ltd. Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung
FR2698560B1 (fr) * 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5260478A (en) * 1992-12-08 1993-11-09 Sterling Winthrop Inc. Iodinated aroyloxy carboxamides
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5264610A (en) * 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
US5811404A (en) 1993-05-14 1998-09-22 Cytel Corporation Sialyl Lex analogues as inhibitors of cellular adhesion
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
KR970011130B1 (ko) * 1993-09-15 1997-07-07 대우전자 주식회사 비디오 테이프 레코더의 오디오/제어 헤드 조립체
IT1265312B1 (it) * 1993-12-21 1996-10-31 Indena Spa Formulazioni contenenti carotenoidi e procarotenoidi associati a polifenoli nella prevenzione dei danni da abnorme produzione di
US6177104B1 (en) * 1994-01-27 2001-01-23 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving dosage form
BE1008307A3 (fr) * 1994-06-16 1996-04-02 Europharmaceuticals Sa Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation.
JPH08151322A (ja) * 1994-09-30 1996-06-11 Takeda Chem Ind Ltd 経口徐放剤
US5521168A (en) * 1994-10-13 1996-05-28 Alcon Laboratories, Inc. Estrogen metabolites for lowering intraocular pressure
US5466440A (en) * 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5585108A (en) * 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5853756A (en) * 1995-01-11 1998-12-29 J. B. Chemicals & Pharmaceuticals Limited Controlled release formulations of Ranitidine
US5503723A (en) * 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5632996A (en) * 1995-04-14 1997-05-27 Imaginative Research Associates, Inc. Benzoyl peroxide and benzoate ester containing compositions suitable for contact with skin
US5811388A (en) 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
CA2232152C (fr) * 1995-12-27 2007-02-06 Janssen Pharmaceutica N.V. Forme galenique solide bioadhesive
US6231888B1 (en) * 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
KR970061942A (ko) * 1996-02-09 1997-09-12 무또 미노루 복합 입자 수성 현탁액 및 이의 제조 방법
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
MX9801835A (es) * 1996-07-08 1998-08-30 Mendell Co Inc Edward Matriz de liberacion sostenida para medicamentos insolubles de dosis altas.
DE59709127D1 (de) * 1996-07-08 2003-02-20 Ciba Sc Holding Ag Triazinderivate als UV-Filter in Sonnenschutzmitteln
WO1998007414A1 (fr) * 1996-08-22 1998-02-26 Research Triangle Pharmaceuticals Ltd. Compositions comprenant des microparticules de substances insolubles dans l'eau et procede de preparation associe
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
IN186315B (fr) * 1996-12-12 2001-08-04 Panacea Biotec Ltd
JPH10194996A (ja) * 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物
EP0951278A2 (fr) * 1997-01-03 1999-10-27 ELAN CORPORATION, Plc Formulation de minicomprimes de cisapride a liberation prolongee
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
GB9703552D0 (en) * 1997-02-20 1997-04-09 Dow Corning Polymerisation of cyclosiloxanes in the presence of fillers
US5811425A (en) 1997-03-04 1998-09-22 Abbott Laboratories Heterocyclic compounds as COX-2 inhibitors
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
BE1011045A3 (fr) * 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
US5939091A (en) * 1997-05-20 1999-08-17 Warner Lambert Company Method for making fast-melt tablets
CA2261787C (fr) * 1997-05-30 2006-11-14 Laboratorios Phoenix U.S.A., Inc. Dispositif a osmose multicouches
US20020002294A1 (en) * 1997-09-24 2002-01-03 D' Amato Robert J. Estrogenic compounds as antiangiogenic agents
IE970731A1 (en) * 1997-10-07 2000-10-04 Fuisz Internat Ltd Product and method for the treatment of hyperlipidemia
US6458777B1 (en) * 1998-03-13 2002-10-01 Mucosal Therapeutics Llc Methods and compositions for treating and preventing mucositis
IL140276A0 (en) * 1998-06-19 2002-02-10 Rtp Pharma Inc Processes to generate submicron particles of water-insoluble compounds
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB9913536D0 (en) * 1999-06-10 1999-08-11 Sterix Ltd Use
US6368620B2 (en) * 1999-06-11 2002-04-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
ATE367802T1 (de) * 2000-09-20 2007-08-15 Jagotec Ag Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
WO2003080027A1 (fr) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Compositions nanoparticulaires d'inhibiteurs d'angiogenese
CA2524538A1 (fr) * 2003-05-19 2004-12-02 Baxter International Inc. Preparations pharmaceutiques de petites particules d'anticonvulsivants et d'agents contre la demence et agents immmunosupresseurs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010760A1 (fr) * 1991-12-05 1993-06-10 Alfatec-Pharma Gmbh Medicament a effet retard contenant de l'ibuprofene et son utilisation
WO1993010767A1 (fr) * 1991-12-05 1993-06-10 Alfatec-Pharma Gmbh Forme d'administration perorale de medicaments peptidiques, notamment l'insuline
WO1998035666A1 (fr) * 1997-02-13 1998-08-20 Nanosystems Llc Preparation de pastilles de naproxene nanoparticulaire

Also Published As

Publication number Publication date
JP2013100359A (ja) 2013-05-23
WO2000018374A1 (fr) 2000-04-06
EP1117384A1 (fr) 2001-07-25
US20090297619A1 (en) 2009-12-03
EP2266542A2 (fr) 2010-12-29
JP5641682B2 (ja) 2014-12-17
JP2015131864A (ja) 2015-07-23
CA2346001A1 (fr) 2000-04-06
JP2002525311A (ja) 2002-08-13
US20080124393A1 (en) 2008-05-29
US20110300210A1 (en) 2011-12-08
AU6283299A (en) 2000-04-17
US20070048378A1 (en) 2007-03-01
CA2346001C (fr) 2003-12-30
JP2009019056A (ja) 2009-01-29
US20080248123A1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
EP2266542A3 (fr) Libération regulée de compositions nanoparticulaires
CA2385890A1 (fr) Compositions a liberation regulee contenant de la nimesulide
IL111647A (en) Pharmaceutical compositions comprising microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles and their preparation
EP1476138B8 (fr) Formulations a liberation modifiee d'au moins une forme de tramadol
UA29563C2 (uk) Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду
CA2264238A1 (fr) Forme galenique a liberation prolongee de milnacipran
CA2216828A1 (fr) Excipient pour insufflation, a liberation progressive, destine a des medicaments
CA2315927A1 (fr) Forme de dosage pharmaceutique et orale diffusee par impulsions
CA2358062A1 (fr) Composition de galantamine a liberation controlee
HK33294A (en) Sustained release pharmaceutical compositions and the preparation of particles for use therein
NO20000284D0 (no) Tanninsyre-polymerblandinger for kontrollert frigivelse av farmasoeytiske midler, saerlig i munnhulen
DE69934582D1 (de) Delavirdin tablettenformulierung
WO2003028653A3 (fr) Compositions pharmaceutiques a liberation prolongee
CA2343732A1 (fr) .delta.-lactones .gamma.-phenyl-substituees, leurs analogues, et leurs utilisations
CA2358773A1 (fr) Compositions a liberation controlee amelioree et son procede
EP1048295A3 (fr) Compositions pharmaceutiques contenant du fénofibrate co-micronisé
UA66812C2 (uk) Препаративна форма лікарського засобу із регульованим вивільненням активної речовини
AU2697100A (en) Pharmaceutical capsule compositions containing loratadine and pseudoephedrine
BG105570A (en) Pharmaceutical compositions for modified release insulin sensitiser
AU8229998A (en) Modified glycosides, compositions comprised thereof and methods of use thereof
AU2773597A (en) Pharmaceutical compositions for the sustained release of insoluble active principles
ATE367153T1 (de) Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme
AU2001221695A1 (en) Solid pharmaceutical compositions for controlled release of active substances
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
DE69634080D1 (de) Mittel zur verhinderung der truebung der vorderen linsenkapsel

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1117384

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CLANCY, MAURICE, JOSEPH, ANTHONY

Inventor name: SWANSON, JON

Inventor name: JAIN, RAJEEV, A

Inventor name: HONTZ, ROBERT

Inventor name: DEVANE, JOHN, G.

Inventor name: CUMMING, KENNETH, IAIN

Inventor name: CODD, JANET, ELIZABETH

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/32 20060101ALI20130624BHEP

Ipc: A61K 9/24 20060101ALI20130624BHEP

Ipc: A61K 9/50 20060101ALI20130624BHEP

Ipc: A61K 9/26 20060101AFI20130624BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140201